Trials / Completed
CompletedNCT01098097
Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)
Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 963 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.
Detailed description
This is an observational/non interventional study to collect data on the patient characteristics of those seeking retreatment as well as safety and efficacy information during the first 12 weeks of retreatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peginterferon alpha | Peginterferon alpha given in combination with ribavirin according to local labeling guidelines |
| DRUG | Ribavirin | Ribavirin given in combination with peginterferon alpha according to local labeling guidelines |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-04-02
- Last updated
- 2014-11-26
- Results posted
- 2012-11-20
Source: ClinicalTrials.gov record NCT01098097. Inclusion in this directory is not an endorsement.